Positive Preliminary Results, R&D Investments, and Financial Results - Research Report on MannKind, Anacor, Sangamo,

    Positive Preliminary Results, R&D Investments, and Financial Results -
   Research Report on MannKind, Anacor, Sangamo, Stereotaxis, and Columbia
                                 Laboratories

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, August 19, 2013

NEW YORK, August 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting MannKind
Corporation (NASDAQ: MNKD), Anacor Pharmaceuticals Inc. (NASDAQ: ANAC),
Sangamo Biosciences, Inc. (NASDAQ: SGMO), Stereotaxis Inc. (NASDAQ: STXS), and
Columbia Laboratories Inc. (NASDAQ: CBRX). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

MannKind Corporation Research Report

On August 14, 2013, MannKind Corporation (MannKind) announced positive
preliminary results from Study 171, a Phase 3 clinical study of AFREZZA
(insulin human [rDNA origin]) Inhalation Powder. AFREZZA Inhalation Powder is
an investigational, rapid-acting mealtime insulin therapy administered using
the Company's next generation (Gen2) Dreamboat inhaler, which is being studied
in patients with type 1 diabetes. According to the Company, the study showed
that AFREZZA-Gen2, when compared to insulin aspart, showed non-inferior
decreases in A1c levels, significantly less hypoglycemia, considerable
decreases in fasting blood glucose levels, and significant weight advantage.
Further, the Company stated that changes in pulmonary function observed in the
AFREZZA-Gen2 group were not different from those observed in an AFREZZA
treatment group that used the Company's first-generation (MedTone) inhaler. ^
The Full Research Report on MannKind Corporation - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/044e_MNKD]

--

Anacor Pharmaceuticals Inc. Research Report

On August 8, 2013, Anacor Pharmaceuticals Inc. (Anacor) announced its Q2 2013
financial results. The Company's total revenues increased 33.6% YoY to $3.4
million during the quarter, primarily due to revenue for research services
performed under the Gates foundation Agreement. Net loss stood at $14.1
million, or $0.36 per diluted share, in Q2 2013, compared to net loss of $14.8
million, or $0.47 per diluted share, in Q2 2012. Commenting on the results,
David Perry, CEO of Anacor Pharmaceuticals, said, "We had a busy second
quarter as we finalized preparations for our NDA for tavaborole, which was
submitted on July 26th. This is an exciting time at Anacor as we begin to reap
the benefits of the investments that we've made in drug development over the
last decade and plan the commercialization of our later stage products." The
Full Research Report on Anacor Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/05d8_ANAC]

--

Sangamo Biosciences, Inc. Research Report

On August 14, 2013, Sangamo Biosciences, Inc. (Sangamo) announced that the
United States Patent and Trademark Office (USPTO) has issued a Notice of
Allowance for the U.S. patent application (US 20110301073) titled "Novel
DNA-binding Proteins and Uses Thereof." The Company stated that the claims
cover core architectural aspects of engineered Transcription Activator-Like
Effectors, or TALEs, which enable proteins to be useful in potential
therapeutic applications of genome editing or gene regulation and for the
efficient use of technology in biomedical research and plant applications.
Philip Gregory D. Phil, Sangamo's Vice President of Research and Chief
Scientific Officer, said, "The novel architectures detailed in the issuing
claims are intrinsic to the efficiency and general utility of the TALE
platform and we expect them to be broadly adopted and become the industry
standard." The Company's research in the field, which was initially published
in a paper titled "A TALE Nuclease Architecture for Efficient Genome Editing,"
resulted in the filing of this patent application. The Full Research Report on
Sangamo Biosciences, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/52a6_SGMO]

--

Stereotaxis Inc. Research Report

On August 8, 2013, Stereotaxis Inc. (Stereotaxis) reported its Q2 2013. The
Company's total revenue declined 7.4% YoY to $9.7 million during the quarter.
Net loss was $3 million, or $0.37 per diluted share, in Q2 2013, compared to
net income of $2.8 million, or $0.32 per diluted share, in Q2 2012. Commenting
on the results, William Mills, Stereotaxis Chairman and Interim CEO, said, "In
the second quarter, we achieved sequential improvement in revenue, gross
margin and operating loss and secured two orders for our Niobe® ES system. One
of these orders was a second system sale to a leading U.S. healthcare
provider, which is one of four major integrated delivery networks in the
country to invest in the Epoch™ platform. Furthermore, we saw improved
utilization rates in certain strategic regions through a targeted physician
plan and the implementation of territory assistants focused on driving
clinical adoption. Our plan involves engaging those physicians that represent
the greatest potential for volume growth and facilitating a faster pace of
adoption within our installed base."The Full Research Report on Stereotaxis
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/b071_STXS]

--

Columbia Laboratories Inc. Research Report

On August 7, 2013, Columbia Laboratories Inc. (Columbia Laboratories) reported
its Q2 2013 financial results. The Company's total product revenues increased
29% YoY to $7 million during the quarter. Net income was $2.7 million, or
$0.03 per diluted share, in Q2 2013, compared to net income of $1.9 million,
or $0.02 per diluted share, in Q2 2012. Commenting on the results, Frank
Condella, Columbia's President and CEO, said, "We are pleased to announce
another consecutive quarter of profitability and positive operating cash
flows, reflecting the ongoing promotion and growth of CRINONE by Actavis and
Merck Serono in their respective territories. We continue to strengthen our
financial position, which we believe increases our capability to pursue
strategic options to increase stockholder value." The Full Research Report on
Columbia Laboratories Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/c87b_CBRX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas - CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.